Tresiba lowers risk of hypos in type II diabetes
Tresiba significantly reduced the rate of severe hypoglycaemia by 80% and nocturnal symptomatic hypoglycaemia by 37%.
Read More
Tag: Tresiba
Novo Nordisk’s Tresiba backed for use on NHS Wales
Novo Nordisk’s long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes.
Read More
Six new drugs win funding nod for NHS Scotland
Treatment cost regulators for the NHS in Scotland have approved routine funding for six medicines, offering patients new treatment options for blood cancer, skin cancer, high cholesterol, diabetes, psoriatic arthritis, and infections in people with cystic fibrosis.
Read More
Novo’s Tresiba beats Sanofi’s Lantus on reducing hypoglycaemia
Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those using Sanofi’s Lantus.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
